Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,953,200 | -535,600 | 3,619,600 | 3,322,000 | 2,342,100 |
| Depreciation Amortization | 209,800 | 207,200 | 181,300 | 148,300 | 125,600 |
| Income taxes - deferred | -510,800 | -348,800 | -536,500 | -275,900 | -154,600 |
| Accounts receivable | -347,300 | -99,300 | -84,100 | -358,600 | -274,700 |
| Accounts payable and accrued liabilities | 36,800 | 49,500 | 48,700 | 120,800 | 31,900 |
| Other Working Capital | -1,199,100 | -514,800 | -265,700 | 340,800 | -105,200 |
| Other Operating Activity | 1,488,800 | 749,200 | 574,000 | 832,500 | 678,400 |
| Operating Cash Flow | $3,631,400 | $-492,600 | $3,537,300 | $4,129,900 | $2,643,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -437,600 | -297,700 | -200,400 | -204,700 | -235,000 |
| Net Acquisitions | N/A | N/A | N/A | -295,900 | N/A |
| Purchase Of Investment | -6,396,500 | -7,438,200 | -3,786,500 | -692,700 | -605,200 |
| Sale Of Investment | 5,913,400 | 4,465,600 | 934,200 | 920,000 | 499,300 |
| Purchase Sale Intangibles | 0 | -187,700 | -58,000 | 0 | N/A |
| Other Investing Activity | -24,700 | -499,700 | -89,000 | -47,800 | 0 |
| Investing Cash Flow | $-945,400 | $-3,770,000 | $-3,141,700 | $-321,100 | $-340,900 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 28,300 |
| Debt Repayment | -5,400 | -33,600 | -44,900 | -85,500 | -47,000 |
| Common Stock Issued | 127,700 | 114,600 | 134,600 | 186,300 | 102,000 |
| Common Stock Repurchased | -2,017,400 | -1,177,100 | -427,600 | 0 | -1,425,400 |
| Other Financing Activity | -366,200 | -398,800 | -224,300 | -168,500 | -135,900 |
| Financing Cash Flow | $-2,261,300 | $-1,494,900 | $-562,200 | $-67,700 | $-1,478,000 |
| Exchange Rate Effect | 90,900 | -42,600 | 26,900 | -29,200 | -13,400 |
| Beginning Cash Position | 4,572,200 | 10,372,300 | 10,512,000 | 6,800,100 | 5,988,900 |
| End Cash Position | 5,087,800 | 4,572,200 | 10,372,300 | 10,512,000 | 6,800,100 |
| Net Cash Flow | $515,600 | $-5,800,100 | $-139,700 | $3,711,900 | $811,200 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,631,400 | -492,600 | 3,537,300 | 4,129,900 | 2,643,500 |
| Capital Expenditure | -437,600 | -297,700 | -200,400 | -204,700 | -235,000 |
| Free Cash Flow | 3,193,800 | -790,300 | 3,336,900 | 3,925,200 | 2,408,500 |